Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

BACKGROUND: Infliximab (IFX) has proven to be an effective addition to the therapeutic arsenal for refractory, fistulizing, and steroid dependent Crohn's disease (CD), with efficacy in the induction and maintenance of clinical remission of CD. Our objective in this study is to report the nation...

Descripción completa

Detalles Bibliográficos
Autores principales: Miheller, Pál, Lakatos, Péter L, Horváth, Gábor, Molnár, Tamás, Szamosi, Tamás, Czeglédi, Zsófia, Salamon, Ágnes, Czimmer, József, Rumi, György, Palatka, Károly, Papp, Mária, Jakab, Zsolt, Szabó, Andrea, Gelley, András, Lakatos, László, Barta, Zsolt, Balázs, Csaba, Rácz, István, Zeher, Margit, Döbrönte, Zoltán, Altorjay, István, Hunyady, Béla, Simon, László, Papp, János, Banai, János, Nagy, Ferenc, Lonovics, János, Újszászy, László, Műzes, Györgyi, Herszényi, László, Tulassay, Zsolt
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755473/
https://www.ncbi.nlm.nih.gov/pubmed/19740450
http://dx.doi.org/10.1186/1471-230X-9-66

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755473/
https://www.ncbi.nlm.nih.gov/pubmed/19740450
http://dx.doi.org/10.1186/1471-230X-9-66

Ejemplares similares